Home / News / World News / Article /
AstraZeneca begins COVID-19 dual-use antibody drug trial in UK
Updated On: 26 August, 2020 08:31 AM IST | London | Agencies
The drug has the potential to be given as a preventative option for people exposed to the Coronavirus, and to treat and prevent disease progression in patients already infected

People queue to be tested at a temporary testing centre for the novel coronavirus in the Spanish Basque city of Gernika, on Tuesday. Pic/AFP
UK-headquartered biopharmaceutical giant AstraZeneca on Tuesday announced the start of clinical trials for an antibody drug which offers dual hope to treat and prevent COVID-19. The drug known as AZD7442 has the potential to be given as a preventative option for people exposed to the Coronavirus and to treat and prevent disease progression in patients already infected by the deadly virus.
"This trial is an important milestone in the development of our monoclonal antibody combination to prevent or treat COVID-19," said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, at AstraZeneca.
Trending Stories
ADVERTISEMENT
ADVERTISEMENT


